[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612633":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":35,"responsibleParty":50,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":18,"eligibilityCriteria":58,"healthyVolunteers":55,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":38,"whyStopped":18,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"alpha lipoic acid","EXPERIMENTAL","patients will receive alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA for prophylaxis of the radiation-induced dermatitis (RID) from day 1 of radiation therapy till the end of the study.",[13],"Dietary Supplement: Alpha Lipoic Acid",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","patients will not receive any prophylactic intervention as there is no standard of care for prophylaxis to the radiation-induced dermatitis (RID).",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DIETARY_SUPPLEMENT","Alpha Lipoic Acid","alpha lipoic acid 300 mg three times daily under the trade name of THIOTACID manufactured by EVAPHARMA.",[9],[26],{"name":27,"affiliation":28,"role":29},"Rana Mohamed Elsayed Kelany Abdelkader","Faculty of Pharmacy, Ain Shams University","PRINCIPAL_INVESTIGATOR",[31],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},"CONTACT","00201023262639","rana.mohamed18@pharma.asu.edu.eg",[36],{"facility":37,"status":38,"city":39,"state":18,"zip":18,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Zagazig University Hospitals","RECRUITING","Zagazig","Egypt","EG",{"type":43,"coordinates":44},"Point",[45,46],31.502,30.58768,{"lat":46,"lon":45},[49],{"name":27,"role":32,"phone":33,"phoneExt":18,"email":34},{"type":29,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Rana mohamed","Principal Investigator","100612633","evaluation-of-the-effect-of-alpha-lipoic-acid-on-radiation-induced-dermatitis-in-breast-cancer-patients-100612633",false,"NCT07256119","Evaluation of the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients","Inclusion Criteria:\n\n* Women aged ≥18 years.\n* Histologically confirmed invasive, early-stage breast carcinoma scheduled for adjuvant radiotherapy.\n* Receiving total radiation dose of 40 Gy for 15 sessions.\n\nExclusion Criteria:\n\n* Prior exposure to radiotherapy.\n* Inflammatory or metastatic breast carcinoma.\n* Patients with connective tissue disorders.\n* Patients with skin inflammatory diseases (e.g. ectopic dermatitis).\n* Patients with known allergy or hypersensitivity to alpha lipoic acid.\n* Concomitant use of nonsteroidal anti-inflammatory drugs, corticosteroids, or antioxidant medications.\n* Patients who will fail to sign the written consent.","FEMALE","18 Years","75 Years",{"count":63,"type":64},40,"ESTIMATED","INTERVENTIONAL",[67],"NA","the purpose of this study is to evaluate the Effect of Alpha Lipoic Acid on Radiation Induced Dermatitis in Breast Cancer Patients",[70],"Prevention",[72,73,22,74],"Radiation Induced Dermatitis","RID","Breast Cancer","2025-12-05",{"date":77,"type":78},"2025-12-12","ACTUAL",{"date":80,"type":78},"2024-08-06",{"date":82,"type":64},"2025-12-28",{"name":5,"class":6},1]